Decreased Bone Mineral Density with Off-Label Use of Tenofovir in Children and Adolescents Infected with Human Immunodeficiency Virus

• Published in: The Journal of pediatrics Vol. 152; no. 4; pp. 582 - 584
• Main Authors: Purdy, Julia B., Gafni, Rachel I., Reynolds, James C., Zeichner, Steven, Hazra, Rohan
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.04.2008; Elsevier
• Subjects: Absorptiometry, Photon; Adenine - analogs & derivatives; Adenine - pharmacology; Adenine - therapeutic use; Adolescent; Anti-HIV Agents - pharmacology; Anti-HIV Agents - therapeutic use; Antiretroviral Therapy, Highly Active - adverse effects; Biological and medical sciences; Bone Density - drug effects; Child; Female; General aspects; HIV; HIV Infections - drug therapy; HIV Infections - physiopathology; Human viral diseases; Humans; Infectious diseases; Investigative techniques, diagnostic techniques (general aspects); Male; Medical sciences; Organophosphonates - pharmacology; Organophosphonates - therapeutic use; Osteoarticular system. Muscles; Pediatrics; Radiodiagnosis. Nmr imagery. Nmr spectrometry; Tenofovir; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; BMD; HIV; DXA; TDF; HAART; Highly active antiretroviral therapy; Bone mineral density; Human immunodeficiency virus; Dual-energy x-ray absorptiometry; Tenofovir disoproxil fumarate; Pediatrics; Antiretroviral agent; RNA-directed DNA polymerase; Label; Nucleotide analog; Tenofovir; Reverse transcriptase inhibitor; Nucleoside analog; Antiviral; Child; Human; Immunopathology; Purine nucleotide; Acyclic nucleotide; Enzyme; Transferases; Use; Enzyme inhibitor; AIDS; Organic phosphonate; Immune deficiency; Infection; Nucleotidyltransferases; Viral disease; Adolescent
• ISSN: 0022-3476; 1097-6833; 1097-6833
• DOI: 10.1016/j.jpeds.2007.12.020

5 of 6 children infected with human immunodeficiency virus (HIV) receiving Tenofovir disoproxil fumarate (TDF) experienced absolute decreases in bone mineral density (BMD). 2 pre-pubertal subjects experienced >6% BMD decreases. 1 subject was the smallest child and experienced a 27% decrease, necessitating withdrawal of TDF. Subsequently, her BMD recovered. Monitoring of children infected with HIV who require treatment with TDF is warranted.